ASCO posted the following on X:
“Though ADCs have emerged as a cutting-edge approach to chemotherapy, determining when and how to assess targets in patients with metastatic breast cancer remains an evolving challenge. Yara Abdou and Paola Zagami discuss in a new editorial for ASCO Daily News.”